Neuroimaging Changes in Hereditary Ataxia
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05160883
Collaborator
(none)
500
1
53.8
9.3
Study Details
Study Description
Brief Summary
This study aim to investigate the neuroimaging changes of hereditary ataxia patients, especially in the SCA3 patients in preclinical or mild stage.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Neuroimaging Changes in Hereditary Ataxia
Actual Study Start Date
:
Jun 30, 2021
Anticipated Primary Completion Date
:
Dec 25, 2025
Anticipated Study Completion Date
:
Dec 25, 2025
Outcome Measures
Primary Outcome Measures
- neuroimaging information [from 2021 to 2025]
neuroimaging information approached by MRI, including 3D-T1, T2, DTI, rsfMRI, SWI, ASL were collected
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
- genetically diagnosed as Spinocerebellar ataxia
Exclusion Criteria:
- deny to follow-up
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Second Affiliated Hospital,Zhejiang University School of Medicine | Hangzhou | Zhejiang | China | 310009 |
Sponsors and Collaborators
- Second Affiliated Hospital, School of Medicine, Zhejiang University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier:
NCT05160883
Other Study ID Numbers:
- Wulab-MRI in HA
First Posted:
Dec 16, 2021
Last Update Posted:
Dec 16, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: